Assessing QTc Interval Changes After Droperidol in Emergency Patients
Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients
This study is testing if giving low-dose Droperidol to emergency patients affects their heart rhythm by looking at changes in the QTc interval before and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHRISTUS Health Academic / other |
| Locations | 1 site (Corpus Christi, Texas) |
| Trial ID | NCT06726811 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effects of low-dose Droperidol on QTc interval changes in patients treated in the emergency department. Adult patients aged 18 and older, who are in a cardiac-monitored bed and have an ECG performed, will receive 2.5 mg of IV Droperidol. ECGs will be recorded before and after the administration of Droperidol to assess any significant changes in the QTc interval. The primary outcome is to determine the percentage of patients experiencing a clinically significant increase in QTc after treatment.
Who should consider this trial
Good fit: Ideal candidates include adult emergency department patients aged 18 and older who are in a cardiovascular-monitored bed and have Droperidol ordered.
Not a fit: Patients who are unable to provide consent or have already received Droperidol before the ECG will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the safety of Droperidol regarding its effects on heart rhythm in emergency department patients.
How similar studies have performed: While there have been studies on Droperidol and QTc intervals, this specific observational approach to assess low-dose effects in an emergency setting is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ED patients ages 18 years or older in a cardiovascular-monitored bed who have both an ECG and a 2.5 mg dose of IV droperidol ordered by their treating physician will be eligible for inclusion. Exclusion Criteria: * Refusal to provide consent. * Administration of droperidol before the first ECG is performed. * Inability to complete the consent form and questionnaire due to clinical instability, severe pain, or disorientation as determined by a study physician.
Where this trial is running
Corpus Christi, Texas
- CHRISTUS Spohn Hospital Corpus Christi-Shoreline — Corpus Christi, Texas, United States (Recruiting)
Study contacts
- Study coordinator: Aaron K Bartoe, DO, MS
- Email: aaronkbartoe@gmail.com
- Phone: (863) 532-8408
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.